The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress
Open accessAbstract
Central endocannabinoid signaling is known to be responsive to stressful stimuli; however, there is no research to date characterizing the effects of stress on peripheral endocannabinoid content. The current study examined serum content of the endocannabinoid ligands N-arachidonylethanolamide (anandamide; AEA) and 2-arachidonoylglycerol (2-AG), and the non-cannabinoid N-acyl ethanolamine (NAE) molecules palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) under basal conditions, immediately following the Trier Social Stress Test (TSST), and 30 min thereafter, in 15 medication-free women diagnosed with major depression, and 15 healthy matched controls. Basal serum concentrations of AEA and 2-AG, but not PEA or OEA, were significantly reduced in women with major depression relative to matched controls, indicating a deficit in peripheral endocannabinoid activity. Immediately following the TSST, serum 2-AG concentrations were increased compared to baseline; serum AEA concentration was unchanged at this time point. Serum concentrations of PEA and OEA were significantly lower than baseline 30 min following the cessation of the TSST. The magnitude of these responses did not differ between depressed and control subjects. These are the first data to demonstrate that the peripheral endocannabinoid/NAE system is responsive to exposure to stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The endocannabinoids anandamide (AEA) and 2arachidonoylglycerol (2AG) are endogenously produced lipids that have been found, for instance, to be elevated in blood in response to psychological stress (Hill et al., 2009;Dlugos et al., 2012).”
From Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans (2016) · cites this paper as Hill et al., 2009
In the citing paper
“Similar effects have been found after acute psychological stress (Hill et al., 2009).”
From Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans (2016) · cites this paper as Hill et al., 2009
In the citing paper
“a number of studies have detected reduced levels of AEA in patients suffering from stress-related psychiatric illnesses, including major depression (Hill et al., 2009) and PTSD (Neumeister et al., 2013).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Hill et al., 2009
In the citing paper
“two independent studies have now both reported that 2-AG levels are reduced in individuals with major depression (Hill et al., 2008; Hill et al., 2009)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Hill et al., 2009
In the citing paper
“EC plasma concentrations are also modified by the presence of affective disorders and severe mental illness [7], [8].”
From Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder (2013) · cites this paper as [7]
In the citing paper
“there are a number of recent studies which demonstrated that EC and NAE blood concentrations increase in response to acute stress [7], [10] and that they are higher in individuals who show stress tolerance [10] and lower in patients with depression [18].”
From Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder (2013) · cites this paper as [7]
In the citing paper
“The possible protective effects of an activated EC system are illustrated by the fact that patients with major depression show reduced serum ANA and 2-AG concentrations [7]”
From Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder (2013) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
Robins, L. N. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290015001 · Cited by 5,219
Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.272.22.1749 · Cited by 2,648
Utility of a New Procedure for Diagnosing Mental Disorders in Primary Care: The PRIME-MD 1000 Study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.1994.03520220043029 · Cited by 1,873
Endocrinology of the stress response
Charmandari, E., Tsigos, C., & Chrousos, G. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.120816 · Cited by 1,799
Fu, J., Gaetani, S., Oveisi, F., Verme, J., Serrano, A., de Fonseca, F. D., Rosengarth, A., Luecke, H., Giacomo, B. D., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,113
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Pace, T. W. W., Mletzko, T. C., Alagbe, O., Musselman, D. L., Nemeroff, C. B., Miller, A. H., & Heim, C. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1630 · Cited by 810
Cited by
Sorted by citations
Psychogios, N., Hau, D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I. V., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016957 · Cited by 1,779
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 449
Hill, M. N., & Tasker, J. G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.030 · Cited by 346
Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256
Self-citationAcute stress increases circulating anandamide and other N-acylethanolamines in healthy humans
Dlugos, A., Childs, E., Stuhr, K. L., Hillard, C. J., & de Wit, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.100 · Cited by 248
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 250
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Hill, M. N., & McEwen, B. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.001 · Cited by 235
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development
Meyer, H. C., Lee, F. S., & Gee, D. G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.143 · Cited by 238
Hauer, D., Schelling, G., Gola, H., Campolongo, P., Morath, J., Roozendaal, B., Hamuni, G., Karabatsiakis, A., Atsak, P., Vogeser, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062741 · Cited by 200
Hillard, C. J., Weinlander, K. M., & Stuhr, K. L. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.11.020 · Cited by 190
Endocannabinoid signalling: has it got rhythm?
Vaughn, L. K., Denning, G., Stuhr, K. L., de Wit, H., Hill, M. N., & Hillard, C. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00790.x · Cited by 176
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Hill, M. N., Hillard, C. J., Bambico, F. R., Patel, S., Gorzalka, B. B., & Gobbi, G. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.006 · Cited by 175
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
The endocannabinoid system and psychiatric disorders
Parolaro, D., Realini, N., Viganò, D., Guidali, C., & Rubino, T. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.018 · Cited by 151
The endocannabinoid system: An emotional buffer in the modulation of memory function
Morena, M., & Campolongo, P. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.010 · Cited by 153
Palmitoylethanolamide: A Natural Compound for Health Management
Clayton, P., Hill, M., Bogoda, N. O., Subah, S., & Venkatesh, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105305 · Cited by 153
Motion Sickness, Stress and the Endocannabinoid System
Choukèr, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., Vogeser, M., Thiel, M., & Schelling, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010752 · Cited by 140
Stress-induced blood brain barrier disruption: Molecular mechanisms and signaling pathways
Welcome, M. O., & Mastorakis, N. E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104769 · Cited by 139
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
Endocannabinoid signalling modulates susceptibility to traumatic stress exposure
Bluett, R. J., Báldi, R., Haymer, A., Gaulden, A. D., Hartley, N. D., Parrish, W. P., Baechle, J. J., Marcus, D. J., Bey, R. M., Shonesy, B. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14782 · Cited by 140
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Hill, M. N., Hillard, C. J., & McEwen, B. S. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq280 · Cited by 136
Oleic acid-derived oleoylethanolamide: A nutritional science perspective
Bowen, K. J., Kris‐Etherton, P. M., Shearer, G. C., West, S. G., Reddivari, L., & Jones, P. J. H. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.04.001 · Cited by 120
Gorzalka, B. B., & Hill, M. N. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.021 · Cited by 120
Endocannabinoid concentrations in hair are associated with PTSD symptom severity
Wilker, S., Pfeiffer, A., Elbert, T. R., Ovuga, E., Karabatsiakis, A., Krumbholz, A., Thieme, D., Schelling, G., & Kolassa, I. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.010 · Cited by 116
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 120
Anhedonia in depression symptomatology: appetite dysregulation and defective brain reward processing
Coccurello, R. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112041 · Cited by 106
Endocannabinoid Signaling in the Control of Social Behavior
Don, W., Allsop, S. A., Tye, K. M., & Piomelli, D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.005 · Cited by 120
Bedse, G., Hartley, N. D., Neale, E., Gaulden, A. D., Patrick, T. A., Kingsley, P. J., Uddin, M. J., Plath, N., Marnett, L. J., & Patel, S. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.002 · Cited by 108
Bosch-Bouju, C., Larrieu, T., Linders, L., Manzoni, O. J., & Layé, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.082 · Cited by 100
Sayd, A., Antón, M., Alén, F., Caso, J. R., Pavon, J., Leza, J. C., de Fonseca, F. R., García‐Bueno, B., & Orío, L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu111 · Cited by 102
Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder
Pinna, G., & Rasmusson, A. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00256 · Cited by 94
Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain
Porta, C. L., Bura, S. A., Llorente‐Onaindia, J., Pastor, A., Navarrete, F., García‐Gutiérrez, M. S., de la Torre, R., Manzanares, J., Monfort, J., & Maldonado, R. J. (2015) · Pain · doi:10.1097/j.pain.0000000000000260 · Cited by 97
Olango, W., Roche, M., Ford, G., Harhen, B., & Finn, D. P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01478.x · Cited by 93
Fernandes, M. F., Mutch, D. M., & Leri, F. (2017) · Nutrients · doi:10.3390/nu9030298 · Cited by 94
Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder
Meyer, J. D., Crombie, K. M., Cook, D. B., Hillard, C. J., & Koltyn, K. F. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002006 · Cited by 90
Locci, A., & Pinna, G. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.02.006 · Cited by 90
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
Finn, D. P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.05.011 · Cited by 91
Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse
Orío, L., Alén, F., Pavón, F. J., Serrano, A., & García‐Bueno, B. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00490 · Cited by 91
Endocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 91
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Roche, M., & Finn, D. P. (2010) · Pharmaceuticals · doi:10.3390/ph3082517 · Cited by 88
Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity
Segev, A., Korem, N., Zer‐Aviv, T. M., Abush, H., Lange, R., Sauber, G., Hillard, C. J., & Akirav, I. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0135-4 · Cited by 81
Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Hillard, C. J., & Liu, Q.-S. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660735 · Cited by 82
The endocannabinoid system in mental disorders: Evidence from human brain studies
Ibarra‐Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, Á., & Callado, L. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.009 · Cited by 84
Endocannabinoid system in psychotic and mood disorders, a review of human studies
Ramesh, R. G., Watts, J. J., & Mizrahi, R. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110096 · Cited by 83
Endocannabinoids: Effectors of glucocorticoid signaling
Balsevich, G., Petrie, G. N., & Hill, M. N. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.07.005 · Cited by 82
Neumeister, A., Seidel, J., Ragen, B., & Pietrzak, R. H. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.012 · Cited by 76
Bedse, G., Hill, M. N., & Patel, S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.015 · Cited by 78
Griebel, G., Stemmelin, J., Lopez‐Grancha, M., Fauchey, V., Slowinski, F., Pichat, P., Dargazanli, G., Abouabdellah, A., Cohen, C., & Bergis, O. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-20895-z · Cited by 77
A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System
Desai, S., Borg, B. A., Cuttler, C., Crombie, K. M., Rabinak, C. A., Hill, M. N., & Marusak, H. A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0113 · Cited by 73
Rahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 77
Lipidomics applications in health, disease and nutrition research
MURPHY, S. A., & Nicolaou, A. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200863 · Cited by 74
Endocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 72
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 71
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.006 · Cited by 70
Effects of parabolic flight and spaceflight on the endocannabinoid system in humans
Strewe, C., Feuerecker, M., Nichiporuk, I., Kaufmann, I., Hauer, D., Morukov, B., Schelling, G., & Choukèr, A. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0057 · Cited by 63
Consideration of sex and gender differences in addiction medication response
McKee, S. A., & McRae‐Clark, A. L. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00441-3 · Cited by 67
Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder
Crombie, K. M., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2018) · Journal of Traumatic Stress · doi:10.1002/jts.22253 · Cited by 68
Hindocha, C., Cousijn, J., Rall, M., & Bloomfield, M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1652380 · Cited by 65
Wieck, A., Grassi-Oliveira, R., do Prado, C. H., Rizzo, L. B., de Oliveira, A. S., Kommers-Molina, J., Viola, T. W., Teixeira, A. L., & Bauer, M. E. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.07.005 · Cited by 63
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity‐an updated review
Payahoo, L., Khajebishak, Y., & Ostadrahimi, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27913 · Cited by 64
Crombie, K. M., Leitzelar, B. N., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2019) · Biological Psychology · doi:10.1016/j.biopsycho.2019.04.002 · Cited by 64
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Martin, E. L., Strickland, J. C., Schlienz, N. J., Munson, J., Jackson, H., Bonn‐Miller, M. O., & Vandrey, R. G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.729800 · Cited by 62
Cedernaes, J., Fanelli, F., Fazzini, A., Pagotto, U., Broman, J.-E., Vogel, H., Dickson, S. L., Schiöth, H. B., & Benedict, C. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.09.014 · Cited by 59
Endocannabinoids, exercise, pain, and a path to health with aging
Watkins, B. A. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.10.001 · Cited by 59
Endocannabinoid‐related lipids are increased during an episode of cyclic vomiting syndrome
Venkatesan, T., Zadvornova, Y., Raff, H., & Hillard, C. J. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12843 · Cited by 58
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity
Fitzgibbon, M., Finn, D. P., & Roche, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv095 · Cited by 60
Gao, W., Walther, A., Wekenborg, M., Penz, M. S., & Kirschbaum, C. (2020) · Talanta · doi:10.1016/j.talanta.2020.121006 · Cited by 58
Newsom, R. J., Osterlund, C., Masini, C. V., Day, H. E., Spencer, R. L., & Campeau, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.11.043 · Cited by 54
Metabolite profiling in posttraumatic stress disorder
Karabatsiakis, A., Hamuni, G., Wilker, S., Kolassa, S., Renu, D., Kadereit, S., Schauer, M., Hennessy, T., & Kolassa, I. (2015) · Journal of Molecular Psychiatry · doi:10.1186/s40303-015-0007-3 · Cited by 53
Mitjans, M., Serretti, A., Fabbri, C., Gastó, C., Catalán, R., Fañanás, L., & Arias, B. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2995-y · Cited by 52
Yi, B., Ничипорук, И. А., Nicolas, M., Schneider, S., Feuerecker, M., Vassilieva, G. Y., Thieme, D., Schelling, G., & Choukèr, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.004 · Cited by 51
Romero‐Sanchiz, P., Nogueira‐Arjona, R., Pastor, A., Araos, P. F., Serrano, A., Boronat, A., García‐Marchena, N., Mayoral, F., Bordallo-Aragón, A., Alén, F., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.026 · Cited by 53
Characterization of serotonin neurotransmission in knockout mice: implications for major depression
Domínguez-López, S., Howell, R. D., & Gobbi, G. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0044 · Cited by 52
Schizophrenia and depression, two poles of endocannabinoid system deregulation
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Callado, L. F., Meana, J. J., & Garzón-Niño, J. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0029-y · Cited by 52
Payahoo, L., Khajebishak, Y., Jafarabadi, M. A., & Ostadrahimi, A. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.056 · Cited by 51
Thieme, U., Schelling, G., Hauer, D., Greif, R. T., Dame, T., Laubender, R. P., Bernhard, W. R., Thieme, D., Campolongo, P., & Theiler, L. G. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1561 · Cited by 50
Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder
Ogawa, S., Hattori, K., Sasayama, D., Yokota, Y., Matsumura, R., Matsuo, J., Ota, M., Hori, H., Teraishi, T., Yoshida, S., et al. (2015) · Scientific Reports · doi:10.1038/srep07796 · Cited by 48
Bassi, M. S., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00424 · Cited by 51
Suárez, J., Rivera, P., Llorente, R., Romero‐Zerbo, S., Bermúdez‐Silva, F. J., de Fonseca, F. R., & Viveros, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.042 · Cited by 48
Ogawa, S., & Kunugi, H. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225212 · Cited by 48
Neumeister, A. (2013) · Depression and Anxiety · doi:10.1002/da.22031 · Cited by 47
Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence
Micale, V., Tabiová, K., Kučerová, J., & Drago, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_5 · Cited by 47
Zamberletti, E., Piscitelli, F., Castro, V. D., Murru, E., Gabaglio, M., Colucci, P., Fanali, C., Prini, P., Bisogno, T., Maccarrone, M., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m068387 · Cited by 48
Serum contents of endocannabinoids are correlated with blood pressure in depressed women
Ho, W. ‐. V., Hill, M. N., Miller, G. E., Gorzalka, B. B., & Hillard, C. J. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-32 · Cited by 46
Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids
Appiah‐Kusi, E., Leyden, E., Parmar, S. R., Mondelli, V., McGuire, P. K., & Bhattacharyya, S. (2015) · Psychological Medicine · doi:10.1017/s0033291715001786 · Cited by 46
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 47
Locci, A., & Pinna, G. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.014 · Cited by 42
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Navarro, D., Gasparyan, A., Navarrete, F., Torregrosa, A. B., Rubio, G., Marín, M., Acosta, G. B., García‐Gutiérrez, M. S., & Manzanares, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094764 · Cited by 47
Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence
Bright, U., & Akirav, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105526 · Cited by 48
Inserra, A., Giorgini, G., Lacroix, S., Bertazzo, A., Choo, J. M., Markopolous, A., Grant, E., Abolghasemi, A., Gregorio, D. D., Flamand, N., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15977 · Cited by 41
Metadata
- Authors
- Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J.
- Affiliations
- University of British Columbia (CA)
- Medical College of Wisconsin (US)
- Venue
- Psychoneuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 34
- Issue
- 8
- Pages
- 1257-1262
- ISSN
- 0306-4530 (ISSN-L)
- PMC
- PMC2716432
- OpenAlex
- W2097199164
- Cited by
- 328
- References
- 30
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 29 · 2023: 19 · 2022: 25 · 2021: 37 · 2020: 23 · 2019: 22 · 2018: 22 · 2017: 17 · 2016: 15 · 2015: 18 · 2014: 8 · 2013: 20 · 2012: 12
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychoneuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA009155)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Keywords
- endocannabinoids, N-acylethanolamines, major depressive disorder, social stress, anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, oleoylethanolamide, serum biomarkers, Trier Social Stress Test, women, stress response
- MeSH terms
- Adult, Amides, Arachidonic Acids, Major Depressive Disorder, Ethanolamines, Female, Glycerides, Humans, Oleic Acids, Palmitic Acids, Stress, Psychological, Case-Control Studies, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
